Publications by authors named "Godfrey J Rainey"
Article Synopsis
- Combining PD-1 blockade with CTLA4 inhibition can be more effective but often leads to serious side effects, limiting how much CTLA4 treatment can be given.
- MEDI5752 is a new type of bispecific antibody that selectively targets PD-1 activated T cells and has a unique mechanism that reduces the necessary dose for a therapeutic effect, including rapid degradation of PD-1.
- Early results show that MEDI5752 can enhance tumor targeting and activity, leading to positive responses in patients with advanced solid tumors, highlighting its potential as an improved cancer immunotherapy strategy.
Bispecific antibodies containing single-chain variable fragment (scFv) appended to immunoglobulins G offer unique development challenges. Here, we describe the stability of a novel bispecific format, BiS5, where the scFv is tethered to the C3 domain. BiS5 showed an improved conformational and chemical stability compared with that of BiS4 in which the scFv is appended in the hinge region between the F and F.
View Article and Find Full Text PDFWidespread drug resistance due to empiric use of broad-spectrum antibiotics has stimulated development of bacteria-specific strategies for prophylaxis and therapy based on modern monoclonal antibody (mAb) technologies. However, single-mechanism mAb approaches have not provided adequate protective activity in the clinic. We constructed multifunctional bispecific antibodies, each conferring three mechanisms of action against the bacterial pathogen Pseudomonas aeruginosa by targeting the serotype-independent type III secretion system (injectisome) virulence factor PcrV and persistence factor Psl exopolysaccharide.
View Article and Find Full Text PDF